Workflow
生物医药科技创新
icon
Search documents
着力打造“兽用疫苗研发生产第一城”
Ke Ji Ri Bao· 2025-06-21 00:51
Core Viewpoint - The city of Hohhot is striving to become the leading hub for veterinary vaccine research and production in China, driven by significant technological breakthroughs and supportive policies in the biopharmaceutical industry [1][3][5] Group 1: Technological Breakthroughs - Jin Yu Bao Ling Biopharmaceutical Co., Ltd. launched the "Jin Niu Zhi" vaccine, marking a major technological advancement in China's biopharmaceutical sector [1] - The company has also established an intelligent manufacturing line capable of producing 8 million doses of pet vaccines annually, which has passed GMP static acceptance [1] - The establishment of the Inner Mongolia Animal Vaccine Technology Innovation Center aims to enhance vaccine research and development, focusing on major animal diseases [2][3] Group 2: Industry Growth and Collaboration - Hohhot has seen its biopharmaceutical industry output grow from 13.11 billion yuan in 2020 to 20.25 billion yuan in 2024, with 117 research institutions and 602 drug registration approvals [4] - The city has actively collaborated with prestigious institutions like the Chinese Academy of Sciences and Tsinghua University to accelerate vaccine development [4] - The introduction of high-value product projects by local companies aims to enhance the quality and innovation of animal serum and vaccine production [2][4] Group 3: Policy Support and Investment - Hohhot has implemented various policies to support the high-quality development of the biopharmaceutical industry, including financial incentives totaling 14 million yuan for innovation platforms and vaccine projects [3] - The city is positioning itself as a national leader in veterinary vaccine production, with significant investments in research and development infrastructure [5] - The establishment of the National Swine Technology Innovation Center in Inner Mongolia signifies the region's commitment to becoming a key player in the animal vaccine industry [4]
从实验室到市场化 广东“靶向”施策激发生物医药创新活力
Core Insights - The Guangdong province is experiencing a surge in biopharmaceutical innovation, with numerous companies achieving breakthroughs in research and moving towards marketization and industrialization [2][3][4]. Group 1: Innovation Achievements - Guangzhou Lupu Pharmaceutical's BTK inhibitor, Rocbrutinib, has had its new drug application accepted by the National Medical Products Administration (NMPA) and is undergoing priority review, potentially becoming the first domestic BTK inhibitor for treating mantle cell lymphoma [3]. - The innovative drug "Angladiwe" has been approved by the NMPA, marking it as the world's first targeted PB2 subunit flu drug, showcasing China's capability in leading drug development [4]. - In 2024, Guangdong has approved 19 innovative drugs and 14 innovative medical devices, representing a 173% and 156% increase compared to 2023, respectively [4]. Group 2: Policy and Industry Support - The rapid growth of Guangdong's biopharmaceutical industry is attributed to strong industrial foundations and unique competitive advantages, with an annual revenue growth rate exceeding 10% for large-scale biopharmaceutical enterprises [5]. - The Guangdong government is implementing reforms to accelerate the approval process for innovative drugs and medical devices, including a 50% reduction in the registration review time for second-class medical devices [6]. Group 3: Challenges and Recommendations - Despite the robust industry foundation, challenges such as insufficient strength of enterprises, an incomplete industrial support system, and a shortage of high-end talent persist [7]. - Recommendations include enhancing regional collaboration, optimizing tax incentives, and encouraging financial institutions to increase support for the biopharmaceutical sector to attract more social capital [7].